Compare Baxter International Inc (BAX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs GeneDx Holdings Corp — how do they compare? Baxter International Inc trades at $27.18 (market cap $14.27B), while GeneDx Holdings Corp trades at $82.11 (market cap $2.44B). The key difference: Baxter International Inc is far larger — about 5.8× GeneDx Holdings Corp's market cap, and Baxter International Inc pays a 0.14% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BAX | WGS | |
|---|---|---|
Market Cap | $14.27B | $2.44B |
Sector | Health | Technology |
52-Week High | $28.35 | $167.51 |
52-Week Low | $15.80 | $34.51 |
Enterprise Value | $21.79B | $2.48B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.09, down 2.48% today but showing strong technical momentum with bullish moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations by 53%, and raised full-year guidance. Despite negative net margins and elevated P/E ratio of 87.85, improving operational performance and positive cash flow projections for 2026 suggest potential turnaround.
The stock presents a mixed outlook with strong technical momentum and recent operational improvements offset by valuation concerns and profitability challenges. Key opportunities include continued execution on raised guidance and debt reduction efforts, while risks center on margin pressure and high debt levels. Analyst consensus leans neutral with 55.55% hold ratings and $25.43 price target below current levels.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
